Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies
Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
178, С. 117252 - 117252
Опубликована: Авг. 3, 2024
Chimeric
antigen
receptor
T
(CAR-T)
cell
therapy
has
shown
promise
in
treating
hematological
malignancies
and
certain
solid
tumors.
However,
its
efficacy
is
often
hindered
by
negative
relapses
resulting
from
escape.
This
review
firstly
elucidates
the
mechanisms
underlying
escape
during
CAR-T
therapy,
including
enrichment
of
pre-existing
target-negative
tumor
clones,
gene
mutations
or
alternative
splicing,
deficits
processing,
redistribution,
lineage
switch,
epitope
masking,
trogocytosis-mediated
loss.
Furthermore,
we
summarize
various
strategies
to
overcome
escape,
evaluate
their
advantages
limitations,
propose
future
research
directions.
Thus,
aim
provide
valuable
insights
enhance
effectiveness
therapy.
Язык: Английский
CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors
Yonggui Tian,
Liubo Zhang,
Yu P
и другие.
Cancer Immunology Immunotherapy,
Год журнала:
2025,
Номер
74(2)
Опубликована: Янв. 3, 2025
Язык: Английский
SPRY1 regulates macrophage M1 polarization in skin aging and melanoma prognosis
Translational Oncology,
Год журнала:
2025,
Номер
54, С. 102331 - 102331
Опубликована: Фев. 28, 2025
Язык: Английский
Fibroblast activation protein-targeted chimeric antigen-receptor-modified NK cells alleviate cardiac fibrosis
International Immunopharmacology,
Год журнала:
2025,
Номер
157, С. 114760 - 114760
Опубликована: Май 3, 2025
Язык: Английский
The progress and prospects of targeting the adenosine pathway in cancer immunotherapy
Biomarker Research,
Год журнала:
2025,
Номер
13(1)
Опубликована: Май 19, 2025
Abstract
Despite
the
notable
success
of
cancer
immunotherapy,
its
effectiveness
is
often
limited
in
a
significant
proportion
patients,
highlighting
need
to
explore
alternative
tumor
immune
evasion
mechanisms.
Adenosine,
key
metabolite
accumulating
hypoxic
regions,
has
emerged
as
promising
target
oncology.
Inhibiting
adenosinergic
pathway
not
only
inhibits
progression
but
also
holds
potential
enhance
immunotherapy
outcomes.
Multiple
therapeutic
strategies
targeting
this
are
being
explored,
ranging
from
preclinical
studies
clinical
trials.
This
review
examines
complex
interactions
between
adenosine,
receptors,
and
microenvironment,
proposing
axis
boost
anti-tumor
immunity.
It
evaluates
early
data
on
pharmacological
inhibitors
discusses
future
directions
for
improving
responses.
Язык: Английский
Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions
Translational Oncology,
Год журнала:
2024,
Номер
49, С. 102086 - 102086
Опубликована: Авг. 24, 2024
Photodynamic
therapy
(PDT)
is
considered
as
a
promising
anticancer
approach,
owning
to
its
high
efficiency
and
spatiotemporal
selectivity.
Ample
evidence
indicated
that
PDT
can
trigger
immunogenic
cell
death
by
releasing
antigens
activate
immune
cells
promote
anti-tumor
immunity.
Nevertheless,
the
inherent
nature
of
tumors
their
complex
heterogeneity
often
limits
PDT,
which
be
overcome
with
novel
strategy
photo-immunotherapy
(PIT)
strategy.
By
exploring
principles
induction
ICD
enhancement,
combined
other
therapies
such
chemotherapy
or
checkpoint
blockade,
tailored
solutions
designed
address
specific
challenges
drug
resistance,
hypoxic
conditions,
tumor
immunosuppressive
microenvironments
(TIMEs),
enables
targeted
enhancement
systemic
immunity
most
distant
recurrent
cancers.
The
present
article
summarizes
strategies
PIT
discusses
recent
existing
limitations.
More
importantly,
we
anticipate
perspectives
presented
herein
will
help
clinical
translation
associated
PIT.
Язык: Английский
Natural killer cell-based cancer immunotherapy: from basics to clinical trials
Experimental Hematology and Oncology,
Год журнала:
2024,
Номер
13(1)
Опубликована: Окт. 16, 2024
Cellular
immunotherapy
exploits
the
capacity
of
human
immune
system
in
self-protection
and
surveillance
to
achieve
anti-tumor
effects.
Natural
killer
(NK)
cells
are
lymphocytes
innate
they
display
a
unique
inherent
ability
identify
eliminate
tumor
cells.
In
this
review,
we
first
introduce
basic
characteristics
NK
physiological
pathological
milieus,
followed
by
discussion
their
effector
function
immunosuppression
microenvironment.
Clinical
strategies
reports
regarding
cellular
therapy
analyzed
context
treatment,
especially
against
solid
tumors.
Given
widely
studied
T-cell
recent
years,
particularly
chimeric
antigen
receptor
(CAR)
therapy,
compare
technical
features
NK-
based
therapies
at
clinical
front.
Finally,
challenges
potential
solutions
for
both
T
cell-based
immunotherapies
treating
malignancies
delineated.
By
overviewing
its
applications,
envision
NK-cell
as
an
up-and-comer
cancer
therapeutics.
Язык: Английский
Liver Metastasis in Cancer: Molecular Mechanisms and Management
MedComm,
Год журнала:
2025,
Номер
6(3)
Опубликована: Фев. 27, 2025
Abstract
Liver
metastasis
is
a
leading
cause
of
mortality
from
malignant
tumors
and
significantly
impairs
the
efficacy
therapeutic
interventions.
In
recent
years,
both
preclinical
clinical
research
have
made
significant
progress
in
understanding
molecular
mechanisms
strategies
liver
metastasis.
Metastatic
tumor
cells
different
primary
sites
undergo
highly
similar
biological
processes,
ultimately
achieving
ectopic
colonization
growth
liver.
this
review,
we
begin
by
introducing
inherent
metastatic‐friendly
features
We
then
explore
panorama
conclude
three
continuous,
yet
distinct
phases
based
on
liver's
response
to
This
includes
metastatic
sensing
stage,
stress
support
stage.
discuss
intricate
interactions
between
various
resident
recruited
cells.
addition,
emphasize
critical
role
spatial
remodeling
immune
Finally,
review
advancements
challenges
faced
management
Future
precise
antimetastatic
treatments
should
fully
consider
individual
heterogeneity
implement
targeted
interventions
stages
Язык: Английский
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy
Journal of Hematology & Oncology,
Год журнала:
2024,
Номер
17(1)
Опубликована: Ноя. 13, 2024
Chimeric
antigen
receptor
(CAR)
cell
therapy
has
achieved
groundbreaking
success
in
treating
hematological
malignancies.
However,
its
application
to
solid
tumors
remains
challenging
due
complex
manufacturing
processes,
limited
vivo
persistence,
and
transient
therapeutic
effects.
In
CAR-immune
cells
induced
by
gene
delivery
systems
loaded
with
CAR
genes
gene-editing
tools
have
shown
efficiency
for
anti-tumor
immunotherapy.
situ
programming
of
autologous
immune
avoids
the
safety
concerns
allogeneic
cells,
manufacture
could
be
standardized.
Therefore,
editing
generation
might
potentially
overcome
abovementioned
limitations
current
therapy.
This
review
mainly
focuses
on
structures,
tools,
techniques
applied
immunotherapy
help
design
develop
The
recent
applications
both
hematologic
malignancies
are
investigated.
To
sum
up,
holds
promise
offering
a
practical,
cost-effective,
efficient,
safe,
widely
applicable
approach
next-generation
Язык: Английский